News headlines about Trinity Biotech (NASDAQ:TRIB) have trended positive on Thursday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trinity Biotech earned a coverage optimism score of 0.32 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.1832658788292 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Separately, Zacks Investment Research lowered Trinity Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, September 20th.
Shares of Trinity Biotech (NASDAQ TRIB) opened at $5.63 on Thursday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.77 and a current ratio of 5.16. Trinity Biotech has a 1 year low of $4.22 and a 1 year high of $7.20. The firm has a market capitalization of $135.35, a P/E ratio of -0.32 and a beta of 1.40.
Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.03. Trinity Biotech had a return on equity of 1.67% and a net margin of 1.74%. The company had revenue of $25.60 million for the quarter, compared to analyst estimates of $25.52 million. research analysts predict that Trinity Biotech will post 0.06 EPS for the current fiscal year.
WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/11/trinity-biotech-trib-given-daily-media-sentiment-rating-of-0-32.html.
Trinity Biotech Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.